Chardan Capital Reiterates Buy on SAB Biotherapeutics, Maintains $3 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae reiterated a Buy rating on SAB Biotherapeutics (NASDAQ:SABS) and maintained a $3 price target.
June 15, 2023 | 8:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital reiterated a Buy rating on SAB Biotherapeutics (NASDAQ:SABS) and maintained a $3 price target.
The Buy rating and maintained $3 price target by Chardan Capital analyst Keay Nakae on SAB Biotherapeutics (NASDAQ:SABS) indicates a positive outlook for the stock. This news is directly related to SABS and is important for investors as it provides a positive sentiment from a reputable analyst, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100